Skip to content

Black Bird Biotech, Inc.: 10-Q filed 2023-08-21

What Black Bird Biotech, Inc. reported in its quarterly report filed 2023-08-21 (fiscal Q2 2023): 39 published measures, 112 facts as tagged in accession 0001477932-23-006351.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-21
Fiscal period
fiscal Q2 2023
Accession
0001477932-23-006351 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Black Bird Biotech, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-30106,349USD
At 2022-12-31218,508USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-30977,638USD
At 2022-12-31868,678USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-30-871,289USD
At 2023-03-31-726,004USD
At 2022-12-31-650,170USD
At 2022-06-30-395,045USD
At 2022-03-31-148USD
At 2021-12-31670,210USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-196,955USD91
2023-01-01 to 2023-06-30-463,889USD181
2022-04-01 to 2022-06-30-522,594USD91
2022-01-01 to 2022-06-30-1,192,952USD181
2022-01-01 to 2022-03-31-670,358USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-113,913USD181
2022-01-01 to 2022-06-30-793,735USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2023-04-01 to 2023-06-3012,922USD91
2023-01-01 to 2023-06-3020,307USD181
2022-04-01 to 2022-06-3030,943USD91
2022-01-01 to 2022-06-3044,745USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-3076,185USD181
2022-01-01 to 2022-06-30346,491USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-06-300USD181
2022-01-01 to 2022-06-300USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-4,743,838USD
At 2022-12-31-4,279,949USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,096,578,714shares91
2023-01-01 to 2023-06-301,318,761,363shares181
2022-04-01 to 2022-06-30328,429,729shares91
2022-01-01 to 2022-06-30327,323,646shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-04-01 to 2023-06-300USD/shares91
2023-01-01 to 2023-06-300USD/shares181
2022-04-01 to 2022-06-300USD/shares91
2022-01-01 to 2022-06-300USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-04-01 to 2023-06-300USD/shares91
2023-01-01 to 2023-06-300USD/shares181
2022-04-01 to 2022-06-300USD/shares91
2022-01-01 to 2022-06-300USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-04-01 to 2023-06-300USD91
2023-01-01 to 2023-06-300USD181
2022-04-01 to 2022-06-300USD91
2022-01-01 to 2022-06-300USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-94,496USD91
2023-01-01 to 2023-06-30-177,270USD181
2022-04-01 to 2022-06-30-480,554USD91
2022-01-01 to 2022-06-30-983,574USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-3096,130USD
At 2022-12-31135,088USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-04-01 to 2023-06-30102,584USD91
2023-01-01 to 2023-06-30286,845USD181
2022-04-01 to 2022-06-3042,040USD91
2022-01-01 to 2022-06-30209,378USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-30973,309USD
At 2022-12-31868,678USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2023-06-30190,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-06-303,189USD
At 2022-12-312,259USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-04-01 to 2023-06-30101,487USD91
2023-01-01 to 2023-06-30187,647USD181
2022-04-01 to 2022-06-30492,842USD91
2022-01-01 to 2022-06-301,001,694USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-06-3077,244USD
At 2022-12-3188,381USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-306,991USD91
2023-01-01 to 2023-06-3010,377USD181
2022-04-01 to 2022-06-3012,288USD91
2022-01-01 to 2022-06-3018,120USD181

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2023-04-01 to 2023-06-305,931USD91
2023-01-01 to 2023-06-309,930USD181
2022-04-01 to 2022-06-3018,655USD91
2022-01-01 to 2022-06-3026,625USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-04-01 to 2023-06-300USD91
2023-01-01 to 2023-06-300USD181
2022-04-01 to 2022-06-300USD91
2022-01-01 to 2022-06-300USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-06-30806,489,235shares
At 2022-12-31310,695,330shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-306,720USD
At 2022-12-3144,448USD
At 2022-06-3052,522USD
At 2021-12-31499,766USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-06-303,070,018USD
At 2022-12-313,320,042USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-01-0917,195USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-06-304,329USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-06-301,000USD
At 2022-12-310USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-102,459USD91
2023-01-01 to 2023-06-30-463,889USD181
2022-04-01 to 2022-06-30-522,594USD91
2022-01-01 to 2022-06-30-1,192,952USD181

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-196,634USD91
2023-01-01 to 2023-03-31-266,934USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-3086,335USD91
2023-01-01 to 2023-06-30156,945USD181
2022-04-01 to 2022-06-30172,048USD91
2022-01-01 to 2022-06-30457,152USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,119USD91
2023-01-01 to 2023-06-302,237USD181
2022-04-01 to 2022-06-301,118USD91
2022-01-01 to 2022-06-302,237USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2023-01-01 to 2023-06-300USD181
2022-01-01 to 2022-06-3031,667USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-06-3015,377USD181
2022-01-01 to 2022-06-305,020USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-01-01 to 2023-06-300USD181
2022-01-01 to 2022-06-300USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-06-30930USD181
2022-01-01 to 2022-06-303,950USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-11,137USD181
2022-01-01 to 2022-06-3017,101USD181

Inspect the source

Entity
Black Bird Biotech, Inc. / CIK 0001409999
Captured
SEC response SHA-256
df936db10ff162447a769152b36bd1ddff9f21ac96d53dd4e87253b660581055

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001409999.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))